ZFIN ID: ZDB-FISH-180130-3
Fish name: slc7a3aihb202Tg/ihb202Tg
Genotype: slc7a3aihb202Tg/ihb202Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by slc7a3aihb202Tg/ihb202Tg
Human Disease Conditions Citations
non-alcoholic fatty liver disease standard conditions Gu et al., 2014
lipid storage disease standard conditions Gu et al., 2014
GENE EXPRESSION
Gene expression in slc7a3aihb202Tg/ihb202Tg
Reporter gene expression No data available
PHENOTYPE
Phenotype in slc7a3aihb202Tg/ihb202Tg
Phenotype Conditions Figures
embryo development delayed, abnormal standard conditions Fig. S2 from Gu et al., 2014
head slc7a3a expression absent, abnormal standard conditions Fig. 1 from Gu et al., 2014
liver lipid increased amount, abnormal fasting, chemical treatment: AICA ribonucleotide Fig. 5 from Gu et al., 2014
liver lipid increased amount, abnormal fasting Fig. 2 from Gu et al., 2014
liver lipid increased amount, abnormal fasting, chemical treatment: dorsomorphin Fig. 5 from Gu et al., 2014
liver lipid increased amount, abnormal fasting, chemical treatment: dorsomorphin, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
liver lipid increased amount, ameliorated fasting, chemical treatment: AMPK activator PT 1 Fig. 5 from Gu et al., 2014
liver lipid increased amount, ameliorated fasting, chemical treatment: 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Fig. 5 from Gu et al., 2014
liver lipid increased amount, ameliorated fasting, chemical treatment: pirinixic acid Fig. 6 from Gu et al., 2014
liver lipid increased amount, ameliorated fasting, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
liver lipid increased amount, ameliorated fasting, chemical treatment: S-nitroso-N-acetyl-D-penicillamine Fig. 5 from Gu et al., 2014
liver lipid normal amount, normal standard conditions Fig. 3 from Gu et al., 2014
liver lipid metabolic process disrupted, abnormal fasting, chemical treatment: AICA ribonucleotide Fig. 5 from Gu et al., 2014
liver lipid metabolic process disrupted, abnormal fasting, chemical treatment: dorsomorphin Fig. 5 from Gu et al., 2014
liver lipid metabolic process disrupted, abnormal fasting Fig. 2 from Gu et al., 2014
liver lipid metabolic process disrupted, abnormal fasting, chemical treatment: dorsomorphin, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
nitric oxide metabolic process decreased process quality, abnormal fasting Fig. 4 from Gu et al., 2014
pharyngeal arch morphology, normal standard conditions Fig. S2 from Gu et al., 2014
whole organism Ab1-prkaa labeling absent, abnormal fasting Fig. 5 from Gu et al., 2014
whole organism Ab1-prkaa labeling absent, abnormal fasting, chemical treatment: AICA ribonucleotide Fig. 5 from Gu et al., 2014
whole organism Ab1-prkaa labeling absent, abnormal fasting, chemical treatment: dorsomorphin Fig. 5 from Gu et al., 2014
whole organism slc7a3a expression absent, abnormal standard conditions Fig. 1 from Gu et al., 2014
whole organism Ab1-prkaa labeling absent, abnormal fasting, chemical treatment: dorsomorphin, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling amount, ameliorated fasting, chemical treatment: dorsomorphin Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling amount, ameliorated fasting, chemical treatment: dorsomorphin Fig. 5 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling amount, ameliorated fasting, chemical treatment: dorsomorphin, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling amount, ameliorated fasting, chemical treatment: 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling amount, ameliorated fasting, chemical treatment: dorsomorphin, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism decreased size, abnormal standard conditions Fig. S2Fig. S3 from Gu et al., 2014
whole organism fertility, normal standard conditions Fig. S3 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling increased amount, abnormal fasting, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling increased amount, abnormal fasting, chemical treatment: S-nitroso-N-acetyl-D-penicillamine Fig. 5 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling increased amount, abnormal fasting, chemical treatment: 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Fig. 5 from Gu et al., 2014
whole organism Ab2-ppargc1a labeling increased amount, abnormal fasting, chemical treatment: AMPK activator PT 1 Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling increased amount, abnormal fasting, chemical treatment: AICA ribonucleotide Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling increased amount, abnormal fasting, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling increased amount, abnormal fasting, chemical treatment: S-nitroso-N-acetyl-D-penicillamine Fig. 5 from Gu et al., 2014
whole organism nos2a expression increased amount, abnormal fasting Fig. 4 from Gu et al., 2014
whole organism Ab1-prkaa labeling increased amount, abnormal fasting, chemical treatment: S-nitroso-N-acetyl-D-penicillamine Fig. 5 from Gu et al., 2014
whole organism Ab1-prkaa labeling increased amount, abnormal fasting, chemical treatment: AMPK activator PT 1 Fig. 5 from Gu et al., 2014
whole organism Ab1-ppara labeling increased amount, abnormal fasting, chemical treatment: AMPK activator PT 1 Fig. 5 from Gu et al., 2014
whole organism Ab1-prkaa labeling increased amount, abnormal fasting, chemical treatment: 4-hydroxy-3-[4-(2-hydroxyphenyl)phenyl]-6-oxo-7H-thieno[2,3-b]pyridine-5-carbonitrile Fig. 5 from Gu et al., 2014
whole organism Ab1-prkaa labeling increased amount, abnormal fasting, chemical treatment: 8-bromo-3',5'-cyclic GMP Fig. 5 from Gu et al., 2014
whole organism size, normal standard conditions Fig. S2 from Gu et al., 2014
whole organism fatty acid increased amount, abnormal fasting Fig. 6 from Gu et al., 2014
whole organism fatty acid increased amount, ameliorated fasting, chemical treatment: pirinixic acid Fig. 6 from Gu et al., 2014
whole organism nitric oxide amount, abnormal fasting Fig. 4 from Gu et al., 2014
whole organism triglyceride increased amount, abnormal fasting Fig. 6 from Gu et al., 2014
whole organism triglyceride increased amount, ameliorated fasting, chemical treatment: pirinixic acid Fig. 6 from Gu et al., 2014

CITATIONS  (1)